Trajan delivers precision to global science
Trajan’s components and consumables business is delivering precision-engineered solutions that ensure accuracy and reliability of laboratory results worldwide.
Trajan’s components and consumables business is delivering precision-engineered solutions that ensure accuracy and reliability of laboratory results worldwide.
Neurizon reports encouraging new rodent preclinical pharmacokinetic data for its lead candidate NUZ-001, showing it effectively crosses the blood-brain barrier.
In this Explorers Podcast, Barry FitzGerald chats with Cullum Winn, managing director of Western Gold Resources, about the company’s path to near-term production at its Gold Duke project in WA’s northern Goldfields.
Sipa Resources MD Andrew Muir goes into the plan of attack on multiple upcoming gold-focused drill campaigns in South Australia.
Everest Metals’ membership in America’s Defense Industrial Base Consortium could secure non-dilutive funding to advance Mt Edon.
Javelin Minerals aims to get its Eureka gold project in WA up and running within a year as gold hits record prices.
The portfolio for capital fund Bailador Technology Investments is outperforming renowned Bessemer Index on key measures, according to its co-founders.
The conversation around personal data protection often swings between two extremes, writes Barry Young – sweeping regulatory control, and blind faith in corporate goodwill.
Ausgold is on the home straight to deliver the key definitive feasibility study for its Katanning gold project in WA’s Great Southern.
These ASX mining juniors could be in the crosshairs as 2025’s next takeover targets according to our expert panel.
Miners and universities are the perfect partners to innovate, problem solve and develop new processing technologies for critical minerals.
Lithium Universe has executed a binding agreement to acquire the global rights to patented photovoltaic solar panel recycling technology.
The ASX finished 0.15pc lower after a subdued day of trading. Investors are keeping to the sidelines as the Iran-Israel conflict evolves.
Lumos Diagnostics has treated its 500th patient in a CLIA waiver study for FebriDx, a move making it more accessible by clinicians.
Original URL: https://www.goldcoastbulletin.com.au/business/stockhead/page/6